Acebilustat

• CAT Number: I005615
• CAS Number: 943764-99-6
• Molecular Formula: C29H27N3O4
• Molecular Weight: 481.54
• Purity: ≥95%
• Target: Aminopeptidase
• Solubility: DMSO; Methanol: ≥ 32 mg/m
• Storage: Store at -20°C
• IUPAC Name: 4-[[(1S,4S)-5-[[4-[4-(1,3-oxazol-2-yl)phenoxy]phenyl]methyl]-2,5-diazabicyclo[2.2.1]heptan-2-yl]methyl]benzoic acid
• InChI: InChI=1S/C29H27N3O4/c33-29(34)23-5-1-20(2-6-23)16-31-18-25-15-24(31)19-32(25)17-21-3-9-26(10-4-21)36-27-11-7-22(8-12-27)28-30-13-14-35-28/h1-14,24-25H,15-19H2,(H,33,34)/t24-,25-/m0/s1
• InChIKey: GERJIEKMNDGSCS-DQEYMECFSA-N
• SMILES: C1[C@H]2CN([C@@H]1CN2CC3=CC=C(C=C3)OC4=CC=C(C=C4)C5=NC=CO5)CC6=CC=C(C=C6)C(=O)O

Acebilustat（Cat No.:I005615）is an oral, small-molecule drug under investigation for its potential in treating autoimmune and inflammatory diseases, particularly rheumatoid arthritis. It functions by inhibiting the enzyme 5-lipoxygenase (5-LOX), which is involved in the production of pro-inflammatory leukotrienes. By reducing leukotriene levels, acebilustat helps to decrease inflammation and prevent tissue damage associated with chronic inflammatory conditions. Early clinical trials have shown promise in improving symptoms and reducing disease activity in patients with rheumatoid arthritis. Ongoing studies aim to further evaluate its long-term safety and efficacy in various inflammatory diseases.